OBJECTIVE: The objective of this study was to investigate body composition redistribution at 3 months after radioactive iodine therapy (RAI). METHODS: Eighty patients with Graves' disease (GD) for RAI and 18 volunteers were recruited. All patients underwent thyroid status test and dual-energy x-ray absorptiometry at baseline and 3 months after RAI. According to the second thyroid status test, patients were divided into the following groups: A, with aggravated hyperthyroidism; B-1, with improved hyperthyroidism; B-2, with euthyroidism; and B-3, with hypothyroidism. RESULTS: Total lean mass (LM) but fat mass (FM) and bone mineral content (BMC) of whole GD patients after RAI recovered to be not different with controls. Compared with baseline, in group A, FM in the left leg increased, and LM in left arm, right arm, trunk and total LM decreased (P o 0.05). In B-2, FM in the head increased, and LM in the head, right arm, trunk and total LM increased (P o0.05). In B-3, FM in the right leg and total body fat percentage decreased, but FM in the head, android-to-gynoid fat ratio and body mass index increased (P o0.05); LM of all sites, weight and total mass increased (P o 0.05); BMC in lumbar spine and left leg, and total BMC decreased (P o0.05). Body composition of unmentioned sites was retained after RAI in each group (P40.05). CONCLUSIONS: Replenishment of LM gets priority rather than FM and BMC during the first 3 months after RAI, and the increase in LM starts from the upper body; head is the regional site in which FM recovery occurs first.
INTRODUCTION
The use of dual-energy X-ray absorptiometry (DXA) for measurement of body composition is becoming more and more widespread in clinical and research settings, because of its advantages of being precise and accurate, measuring bone mineral and adipose tissue distribution simultaneously, permitting regional analysis, being safe and practical and involving only a negligible radiation dose. 1, 2 It allows one to assess body composition by providing the three major composition variables: fat mass (FM), lean mass (LM) and bone mineral content (BMC).
Hyperthyroidism is a catabolic state with increased lipolysis, protein turnover and bone loss, [3] [4] [5] which induces emaciation, muscle weakness, osteopenia and osteoporosis. [6] [7] [8] It can be treated with antithyroid drugs (ATD), radioactive iodine therapy (RAI) or surgically. 9 RAI is a safe, effective modality for definitive treatment of hyperthyroidism: 80-90% of patients achieve euthyroidism within 8 weeks of a single dose of iodine-131, [9] [10] [11] [12] and it is the most frequently used therapy for Graves' disease (GD) in the United States. Of note, precocious hypothyroidism can develop 3 months after RAI. 13, 14 The body composition of GD patients recovers after several months of euthyroidism. [15] [16] [17] It was reported that after 6 months of euthyroidism, fat-free mass increased from a mean of 36.8-40.4 kg in the overt hyperthyroidism group and from a mean of 40.3-42.2 kg in the subclinical hyperthyroidism group. FM increased to approximately the same extent and BMC increased significantly as well as in both groups. 16 FM increased by 5.3 kg and fat-free mass increased by 3.5 kg after 12 months of achieved euthyroidism. 18 In addition, the study by Acotto et al. 15 disclosed that FM increased significantly at 1 year, but it remained unchanged in all of the studied regions after 2 years of treatment.
To our knowledge, most of previous articles focused on changes in body composition 6 months or more after treatment. However, whether and how the body composition restores in the early recovery stage (within 3 months) after RAI, especially of patients with precocious hypothyroidism, remain obscure. In addition, there are a few previous studies that evaluated changes of body composition in each defined regional site after RAI. The site at which the body composition recovers first is unknown. On the basis of this consideration, the purpose of this study is to evaluate the body composition redistribution at 3 months after RAI among patients with GD.
MATERIALS AND METHODS

Patients and methods
This study was approved by the Ethics Committee, and informed consents were obtained from all subjects. Patients with GD who were referred to the nuclear medicine department for RAI were recruited from November 2011 to November 2013. Patients with any contraindication, such as pregnant or lactating patients, acute myocardial infarction, severe kidney failure, or other causes of thyrotoxicosis, as well as patients with diseases that influenced the body composition metabolism, were excluded from this study. Ultimately, 80 subjects with GD entered this study (M/F = 18/62, mean age = 38.2 ± 9.5 years). Of those cases, 57 were pretreated with ATD, and 23 were initially diagnosed as having GD. Eighteen healthy participants were recruited as the control group (M/F = 2/16, mean age = 41.2 ± 8.6 years, body mass index (BMI) = 23.0 ± 1.0 kg/m 2 ).
Diagnosis of GD was based on clinical symptoms, physical examination (diffuse goiter), elevated free triiodothyronine (FT 3 ) and/or free thyroxine (FT 4 ), and suppressed thyroid-stimulating hormone (TSH), positive thyroperoxidaes antibody (TPOAb) and TSH receptor antibody (TRAb), and the results of 3-and 24-h radioactive iodine uptake (RAIU). Serum levels of FT 3 (reference range 3.5-6.5 pmol/l), FT 4 (reference range 11.5-22.7 pmol/l), TSH (reference range 0.55-4.78 μIU/ml), TPOAb (reference range 0-60 U/ml) and TRAb (reference rangeo12 U/l) were determined using a fully automated chemiluminescence analyzer (Centaur, Siemens Healthcare Diagnostics Inc., Walpole, MA, USA) before RAI and 3 months after RAI. RAIU was measured using the iodine-131 dosimeter (reference range for 3 and 24 h was 9-25% and 25-50%, respectively). Technetium 99 m scanning was performed to estimate thyroid weight before RAI.
The single dose of iodine-131 administered was calculated to be 4.44 MBq/g of estimated thyroid tissue × 100 divided by the 24-h RAIU (ultimate dose range 281.2 ± 74.0 MBq). Methimazole and propylthiouracil were stopped 2-7 days and 2-4 weeks before RAI to avoid affecting the curative effect, respectively. β-Blockers were given to control hyperadrenergic symptoms appropriately. Patients with serious Graves' orbitopathy were given corticosteroids before RAI to avoid ophthalmopathy exacerbation. Their baseline characteristics are shown in Table 1 .
Thyroid status seen at the 3-month follow-up visit was classified on purely biochemical grounds: patients with further elevations of FT 3 and/or FT 4 were classified as having aggravated hyperthyroidism, that is, group A (5 patients, 6%), and patients with lower levels of FT 3 and FT 4 were classified as having improved thyroid status, that is, group B (75 patients, 94%). In group B, patients were divided into several subgroups: those with improved hyperthyroidism were defined as B-1 (12 patients, 15%); those with euthyroidism were defined as B-2 (9 patients, 11%); and those with hypothyroidism were defined as B-3 (54 patients, 68%) ( Table 2) .
Assessment of body composition was performed at baseline and 3 months after RAI by a Hologic DXA (Discovery A, version 3.2, Hologic, Inc., Bedford, MA, USA). Whole-body measurements were taken, enabling the quantification of FM and LM and BMC and total mass (TM). Studied regions are defined as described in the operations manual provided by Hologic 19 (Figure 1 ). Patients' weight and height were measured by scale.
Routine quality control was performed before the first patient's bone mineral density measurement to ensure the accuracy of the device. The coefficient of variation (calculated by the precision calculator software provided by ISCD (International Society for Clinical Densitometry) on this device is 1.0% at our department, which is within the limits of ISCD recommendations. 20
Statistical analysis
Statistical analysis was processed by the SPSS software (version 16.0; SPSS Inc., Chicago, IL, USA). Least Significant Difference test was used to assess the interclass difference of thyroid status. Wilcoxon signed-rank tests were used to examine the significance of differences between baseline and subsequent thyroid status and DXA measures of body composition at multiple sites. Regression analysis and Bland-Altman analysis, performed using the MedCalc software (version 9.2.0.1; MedCalc Inc., Ostend, West Flanders, Belgium), were used to evaluate the correlation and agreement between the two patients' weight measurement methods, that is, scale and DXA. A P-value of o0.05 was considered as statistically significant. Data are presented as mean ± s.d.
RESULTS
Characteristics of the control group compared with those of GD patients There was no significant difference between whole GD patients and normal healthy participants in terms of sex (M/F = 18/62 vs 2/16, P = 0.28), age (38.2 ± 9.5 vs 41.2 ± 8.6, P = 0.21) and height (1.60 ± 0.1 vs 1.62 ± 0.1, P = 0.21). When normalized by height, total FM and BMC in whole GD patients were significantly less than that of the control group before (6631.5 ± 1785.0 vs 7561.5 ± 1061.3, P = 0.01, and 753.0 ± 105.1 vs 863.2 ± 73.8, P = 0.00, respectively) and after RAI (6694.2 ± 1673.2 vs 7561.5 ± 1061.3, P = 0.01, and 745.4 ± 97.4, P = 0.00, respectively). Total LM of GD patients was less than that of the control group before treatment (14184.4 ± 2429.1 vs 15101.2 ± 1066.1, P = 0.01), whereas it recovered to be no different from that of the control group after treatment (14715.7 ± 2195.5 vs 15101.2 ± 1066.1, P = 0.19).
Characteristics of GD patients in each group after treatment
Changes in weight and TM 3 months after treatment. There was a correlation between the weight and TM (r = 0.976, Po0.0001), and they agreed sufficiently well with each other, with Bland-Altman limits of − 3.8-3.6 Kg. After treatment, weight and TM increased by 6.0% (P = 0.00, 95% CI: 4.4-7.6%) and 8.1% (P = 0.00, 95% CI: 6.4-9.7%) in group B-3, and remained unchanged in other groups (P40.05).
Changes in total and regional FM 3 months after treatment. In group A, FM in the left leg increased by 5.3% (P = 0.04, 95% CI: 0.3-10.3%). In B-2, FM in the head increased by 2.1% (P = 0.02, 95% CI: 0.8-3.4%) ( Figure 2 ). In B-3, FM in the head, android-to-gynoid fat ratio (AGR) and BMI (BMI, calculated as weight (kg) divided by height (m 2 )) increased by 4.2% (P = 0.00, 95% CI: 3.1-5.3%), 3.8% (P = 0.00, 95% CI: 1.5-6.1%) and 5.9% (P = 0.00, 95% CI: 4.1-7.6%), respectively. However, FM in the right leg and total body fat percentage (TF %, calculated as total FM divided by TM) decreased by 1.9% (P = 0.02, 95% CI: − 5.3-1.5%) and 5.7% (P = 0.00, 95% CI: − 8.3 to − 3.1%), respectively. FM changes in B-1 and FM in arms, trunk, android, gynoid, total FM and FM index (FMI, calculated as FM (kg) divided by height (m 2 )) were not significantly different (P40.05) in any group. Android fat is the fat stored in the midsection of the body, predominantly in the lower abdomen. Gynoid fat is stored primarily around the hips and the thighs.
Changes in total and regional LM 3 months after treatment. In group A, LM in the left arm, right arm, trunk and total LM decreased by 5.0% (P = 0.04, 95% CI: − 7.3 to − 2.6%), 3.9% (P = 0.04, 95% CI: − 6.5 to − 1.3%), 2.0% (P = 0.04, 95% CI: − 4.7-0.7%) and 3.4% (P = 0.04, 95% CI: − 6.5 to − 0.3%), respectively ( Figure 3 ). In B-2, LM in the head, right arm, trunk and total LM increased by 2.1% (P = 0.03, 95% CI: 0.4-3.8%), 9.6% (P = 0.02, 95% CI: 2.6-16.7%), 2.9% (P = 0.02, 95% CI: 1.0-4.9%) and 3.2% (P = 0.02, 95% CI: 0.8-5.6%), respectively. In B-3, LM of all measured sites increased (P o0.05). In addition, the percentage change of B-3 in the right arm, trunk and total LM was higher than that of B-2 (P o 0.05). There were no statistically significant differences in LM of other unmentioned sites and B-2 before and after RAI (P40.05).
Changes in total and regional BMC 3 months after treatment. It is documented that BMC in lumbar spine, left leg and total BMC in group B-3 decreased by 2.2% (P = 0.02, 95% CI: − 6.8-2.3%), 1.2% (P = 0.04, 95% CI: − 2.5-0.1%) and 1.4% (P = 0.02, 95% CI: − 2.6 to − 0.1%), respectively (Figure 4 ). There were no significant differences in BMC of other sites and other groups before and after RAI (P40.05).
DISCUSSION
Before RAI, total FM, LM and BMC of whole GD patients were less than controls. It was consistent with previous reports. [6] [7] [8] Three months after RAI, only total LM recovered to be no different from controls. It may imply that recovery of LM gets priority during this period. Although total FM and BMC in whole GD patients were not significantly different before and after RAI, when they were divided into various groups according to their thyroid status the body composition in each group interestingly changed differently. In this study, the weight and TM agreed sufficiently well with each other, which confirmed that DXA was an accurate method in measuring body composition. 1 Our results showed that weight and TM increased only in B-3. However, when assessing the regional body composition, FM in the head increased in B-2 and B-3 compared with baseline. It was uncertain whether this change contributed to the enlargement of orbital fat 21, 22 or normal pattern of face FM recovery. Of note, nevertheless, no patient was with exacerbating overt ophthalmopathy after RAI. It is well known that the increased thyroid hormone (TH) can result in an exacerbated lipolysis. 23 However, FM of the left leg increased in group A, whereas FM of the right leg decreased in B-3. One of the possible reasons is that the slight myxoedema improves with the decrease in FT 3 and FT 4 . However, patients with hypothyroidism also experience myxoedema. Leptin, a protein that regulates body weight and energy expenditure 24, 25 by neuroendocrine mechanisms, 26, 27 is positively correlated with TSH in both hypothyroidism and hyperthyroidism patients, 28 rather than TH. 29, 30 Leptin can be released from leg skeletal muscle, and the pattern of release is different from subcutaneous adipose tissue. 31 It suggests that leptin may have a role in maintenance of leg FM. Contradictorily, a previous study reported that the FM in the legs did not change within 6 months, at which time the patients had hypothyroidism. 15 The exact reason of change in leg FM remains to be elucidated.
Despite unchanged FM in android and gynoid, AGR significantly increased in B-3. AGR of patients with thyroid dysfunction has Figure 2 .
In group A, FM in LL significantly increased by 5.3% (P = 0.04). In group B-2, FM in H significantly increased by 2.1% (P = 0.02). In group B-3, FM in H, AGR and BMI significantly increased by 4.2% (P = 0.00), 3.8% (P = 0.00) and 5.9% (P = 0.00), respectively, and FM in RL and TF% significantly decreased by 1.9% (P = 0.02) and 5.7% (P = 0.00), respectively. FM changes in group B-1 were not significantly different (P40.05). A, android; AGR, android-to-gynoid fat ratio; BMI, body mass index; FMI, fat mass index; G, gynoid; H, head; LA, left arm; LL, left leg; RA, right arm; RL, right leg; T, total; TF%, total body fat percentage; Tr, trunk. # Po 0.05 vs baseline.
been studied less intensively. A common way to measure the AGR is by using the waist-to-hip ratio, which is positively associated with the level of TSH. 32, 33 BMI is positively related to TSH 34, 35 and negatively related to FT 4. 35 It is thought to be an indicator of how much fat a person has. However, it does not distinguish FM from LM and BMC. 36 Interestingly, although BMI enlarged in B-3, total FM did not increase and TF% reduced, respectively. The reduced TF% may be mainly secondary to the increase in LM. Some previous studies also demonstrated that total FM remained unchanged within 1 year after achieving euthyroidism. 18, 37 Despite the decrease when patients developed short-term hypothyroidism after treatment, TF% was higher compared with healthy controls. 38 Tagliaferri et al. 39 found that TF% was not different between subclinical hypothyroidism and euthyroidism. They concluded that thyroid function affects adiposity only when thyroxine concentrations fall below the normal range. However, they did not evaluate regional FM. In the present study, FM in the head increased after patients achieved normal TH. To some extent, it suggests that the head may be the regional site in which FM first recovers. FMI is an accurate predictor of obesity as well. 40 However, no significant change in FMI was found in any group following RAI in this study. There are a limited number of studies that discuss this parameter in patients with thyroid dysfunction. Thus, we propose that TF% (directly calculate a person's relative FM) may be more suitable and sensitive for assessing obesity than BMI and FMI.
Hyperthyroidism is associated with protein turnover and breakdown 41 because skeletal muscle, primarily the content of LM, is an important target tissue for TH. 42 Muscle mass of patients with hyperthyroidism increases following treatment. 15, 16, 18, 37, 43 LM in the arms, trunk and the legs augmented at 6 months, 1 year and 2 years after the onset of treatment. 15 However, most of studies focus on changes in LM 6 months or more after treatment. This present study showed that LM of arms, trunk and total LM decreased in group A, and LM of head, right arm, trunk and total LM in B-2 and LM in B-3 increased at 3 months after RAI. The increase of LM in B-2 and B-3 was thought to be the result of both protein and water restitution, 18 paralleled by decreased resting metabolic rate 43, 44 attributed to the decrease in TH. The activity of TSH receptor in muscle and the TH-regulated non-coding microRNA pair miR-206/miR-133b are possibly the underlying causes of change in LM. 43, 45, 46 In addition, the percentage change of B-3 in the right arm, trunk and total LM was higher than that of group B-2. Furthermore, there were more sites with increased LM in B-3 than in B-2. The results imply that the increase in LM is TH-dependent, and that it starts from the upper body.
Hyperthyroidism is a known cause of bone loss. 47 It is reported that BMC increased in patients with hyperthyroidism after 6 months of normal thyroid function. 15, 16 However, other studies have given inconsistent results. 18, 37 In this study, BMC of lumbar spine, left leg and total BMC reduced in B-3, whereas there were no significant changes of any site in other groups. Hypothyroidism has received little attention on bone mineral metabolism. A previous study found that bone mineral density was low in hypothyroidism sheep fetuses. 48 However, Gonzalez et al. 49 demonstrated no association between hypothyroidism and decreased BMC. Despite the long-term duration of idiopathic subclinical hypothyroidism, bone health is not impaired in children. 50 Thus, whether the decreased BMC in B-5 was induced by the excess TH released from the impaired cell after RAI remained unsettled. On the other hand, it may imply that bone remodeling of adults patients with hyperthyroidism is a slow and long process after RAI at least to some extent.
Although the TH was reduced remarkably, no significant difference in body composition of any measured site was reached in B-1. Besides, the reduction degree of TH in B-1 was less than that in other subgroups of B. It may imply that the change in body composition occurs when the change in the degree of TH reaches a threshold value. Intuitively, this study demonstrated that more TH lowering produced a higher percentage change and more sites than less TH lowering. In addition, LM in the arm increased more obviously than LM in other sites. Furthermore, the percentage change of LM was higher than that of FM and BMC. To some extent, it indicates that LM is more sensitive to early changes in TH than FM and BMC. 15 Further study is needed to clarify all those hypotheses.
In conclusion, the current study demonstrates that the increase in LM starts from the upper body after RAI. Interestingly, FM in the right leg decreases in patients who achieved hypothyroidism at the first 3 months after RAI. Although BMI increases after treatment, total FM remains unchanged and TF% decreases remarkably, secondary to the increased LM. These alterations in body composition redistribution are different from previous reports. Furthermore, BMC of patients who achieved hypothyroidism decreases, which has been reported less intensively. In some way, the results in this study imply that bone remodeling is a slow Figure 4 . It is documented that BMC in LS, LL and T in group B-3 was significantly decreased: 2.2% (P = 0.02), 1.2% (P = 0.04) and 1.4% (P = 0.02), respectively. There were no statistically significant differences in BMC of other sites and other groups before and after RAI (P40.05). H, head; LA, left arm; RA, right arm; LR, left ribs; RR, right ribs; TS, thoracic spine; LS, lumbar spine; P, pelvis; LL, left leg; RL, right leg; T, total. # Po0.05 vs baseline.
and long process after RAI. At least to some extent, replenishment of body LM gets priority rather than FM and BMC during the first 3 months after RAI. However, further study is needed to clarify all those hypotheses and to evaluate the underlying mechanisms involved in those changes.
